This content is machine translated Chronic lymphocytic leukemia Can CAR T-cell therapy cure CLL? An update Although treatment outcomes have improved, relapsed or refractory chronic lymphocytic leukemia (RRCLL) is still not curable with standard therapies and has a poor prognosis. Long-term data from patients with CLL...…
View Post 6 min This content is machine translated Hematology Overcoming boundaries – basic research, diagnostics and therapy The motto of the recently held Swiss Oncology & Hematology Congress (SOHC) was “Overcoming borders together”. A great deal of research has been and is being carried out to give…
View Post 7 min This content is machine translated Hematology and medical oncology The world of hematology and oncology research The rapid technological developments in diagnostics and innovations in multimodal therapy in the field of hematology and medical oncology were the focus of the annual conference. While immunotherapies with monoclonal…
View Post 7 min This content is machine translated Hematology Blood, blood cells, blood diseases – current research at a glance The most important European meeting of hematologists is held annually in June. Renowned experts will gather at the EHA Annual Congress to present and discuss current research data on various…
View Post 8 min This content is machine translated Hematology The goal in sight: Optimal outcomes for hematology patients In hematology, the annual meeting of the European Hematology Association is one of the dates in the annual schedule. The association promotes excellence in patient care, research and education in…
View Post 2 min This content is machine translated Chronic myeloid leukemia In the long term: first-line therapy with TKI convinces with efficacy Chronic myeloid leukemia is a malignant disease of the bone marrow in which too many white blood cells are produced. In most patients, a genetic alteration of the Philadelphia chromosome…
View Post 2 min This content is machine translated BCL-2 Inhibition The next chapter in blood cancer therapy is opened BCL-2 inhibition represents a milestone in the history of blood cancer treatment. Approved for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL), oral small molecule is now also…
View Post 8 min This content is machine translated ASH in Atlanta The throne wavers ECHELON-1 is the first positive data available on brentuximab vedotin in first-line Hodgkin lymphoma. And things are also progressing in CLL. Chemotherapy-free variants hold their own in recurrences.
View Post 5 min This content is machine translated ICML 2017 in Lugano Long-term data are positive At the ICML Congress, the audience gained insight into long-term data from two phase III trials in mantle cell lymphoma and chronic lymphocytic leukemia. The new results confirm the statements…
View Post 3 min This content is machine translated Neither under nor over treatment Principles of lymphoma therapy in elderly patients The elderly often cannot be treated as aggressively as younger people for cancer. But at the same time, you don’t want to deprive someone of an effective medication “just” because…
View Post 7 min This content is machine translated 57th ASH Meeting in Orlando New field of application for rituximab The ASH Congress was held last year in Orlando. This time, one of the topics was the efficacy of rituximab in adult patients with B-precursor acute lymphoblastic leukemia (ALL). Up…
